TG Therapeutics (TGTX) Misses Q3 EPS by 19c

TG Therapeutics (NASDAQ: TGTX) reported Q3 EPS of ($0.51), $0.19 worse than the analyst estimate of ($0.32). Revenue for the quarter came in at $38.1 million versus the consensus estimate of $30 thousand.

For earnings history and earnings-related data on TG Therapeutics (TGTX) click here.

You May Also Be Interested In

• Paychex (PAYX) Tops Q1 EPS by 2c
• UBS Reiterates Buy Rating on KB Home (KBH) Amid Transition Back to Built-to-Order
• Activist Jana Partners calls for Six Flags sale - WSJ